Alliance Pharma has accepted a revised cash proposal from DBAY Advisors, valuing the company at approximately £362 million ($467.5 million). This agreement marks a significant development for the healthcare group, which is primarily owned by DBAY. Meanwhile, Assura is currently in discussions with a consortium led by KKR, which has raised its offer to nearly £1.61 billion after the UK healthcare landlord previously rejected an earlier bid. The negotiations indicate a growing interest in the UK healthcare sector from private equity firms, as KKR's latest proposal aims to secure a substantial acquisition in this market.